{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:09Z","timestamp":1793459649301,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["the Research Program on HIV\/AIDS\/ 21fk0410030h0003"],"award-info":[{"award-number":["the Research Program on HIV\/AIDS\/ 21fk0410030h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["the Research Program on HIV\/AIDS\/ 22fk0410049h0001"],"award-info":[{"award-number":["the Research Program on HIV\/AIDS\/ 22fk0410049h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2024,3,18]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Patients with haemophilia and HIV who acquire hepatitis C virus (HCV) after receiving contaminated blood products can experience accelerated progression of liver fibrosis and a poor prognosis, making liver disease a prominent cause of mortality among these patients. In the current study, we aimed to evaluate the safety and tolerability of the potential antifibrotic agent OP-724\u2014a CREB-binding protein\/\u03b2-catenin inhibitor\u2014in this patient subset.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>In this single-centre, open-label, non-randomised, phase I trial, we sequentially enrolled patients with cirrhosis following HIV\/HCV coinfection classified as Child-Pugh (CP) class A or B. Five patients received an intravenous infusion of OP-724 at doses of 140 or 280 mg\/m<jats:sup>2<\/jats:sup> for 4\u2009hours two times weekly over 12 weeks. The primary endpoint was the incidence of serious adverse events (SAEs). Secondary endpoints included the incidence of AEs and improved liver stiffness measure (LSM), as determined by vibration-controlled transient elastography. This study was registered at ClinicalTrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04688034\">NCT04688034<\/jats:ext-link>).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between 9 February 2021 and 5 July 2022, five patients (median age: 51 years) were enrolled. All five patients completed 12 cycles of treatment. SAEs were not observed. The most common AEs were fever (60%) and gastrointestinal symptoms (diarrhoea: 20%, enterocolitis: 20%). Improvements in LSM and serum albumin levels were also observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this preliminary assessment, intravenous administration of 140 or 280 mg\/m<jats:sup>2<\/jats:sup>\/4\u2009hours OP-724 over 12 weeks was well tolerated by patients with haemophilia combined with cirrhosis due to HIV\/HCV coinfection. Hence, the antifibrotic effects of OP-724 warrant further assessment in patients with cirrhosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04688034\">NCT04688034<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2023-001341","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T10:20:15Z","timestamp":1714213215000},"page":"e001341","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV\/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04688034","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04688034","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04688034","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-4721","authenticated-orcid":false,"given":"Kiminori","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tanuma","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Yanase","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacokinetics, Division of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunamasa","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"2025073013463161000_11.1.e001341.1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hae.14668","article-title":"Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders","volume":"29","author":"Isfordink","year":"2023","journal-title":"Haemophilia"},{"key":"2025073013463161000_11.1.e001341.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62001-6"},{"key":"2025073013463161000_11.1.e001341.3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12185-008-0144-x","article-title":"Current status of Japanese HIV-infected patients with coagulation disorders: Coinfection with both HIV and HCV","volume":"88","author":"Tatsunami","year":"2008","journal-title":"Int J Hematol"},{"key":"2025073013463161000_11.1.e001341.4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jhep.2011.05.028","article-title":"Influence of interferon-based therapy on liver fibrosis progression in HIV\/HCV Coinfected patients: a retrospective repeated liver biopsy analysis","volume":"56","author":"Ingiliz","year":"2012","journal-title":"J Hepatol"},{"key":"2025073013463161000_11.1.e001341.5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26741"},{"key":"2025073013463161000_11.1.e001341.6","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000198087.47454.e1"},{"key":"2025073013463161000_11.1.e001341.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit768"},{"key":"2025073013463161000_11.1.e001341.8","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/cid\/ciz1140","article-title":"Liver stiffness at the time of sustained virological response predicts the clinical outcome in people living with human immunodeficiency virus and hepatitis C virus with advanced fibrosis treated with direct-acting Antivirals","volume":"71","author":"Corma-G\u00f3mez","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025073013463161000_11.1.e001341.9","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkx223","article-title":"Efficacy and safety of direct antiviral agents in a cohort of Cirrhotic HCV\/HIV-Coinfected patients","volume":"72","author":"Navarro","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025073013463161000_11.1.e001341.10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/hepr.13686","article-title":"Indications and waiting list priority for deceased donor liver transplantation in HIV\/HCV Co-infected Hemophilic patients in Japan through contaminated blood product","volume":"51","author":"Eguchi","year":"2021","journal-title":"Hepatol Res"},{"key":"2025073013463161000_11.1.e001341.11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104069","article-title":"Safety, tolerability, and anti-Fibrotic efficacy of the CBP\/beta-Catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, Multicentre, phase 1\/2A study","volume":"80","author":"Kimura","year":"2022","journal-title":"EBioMedicine"},{"key":"2025073013463161000_11.1.e001341.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-001001","article-title":"Feasibility, safety and tolerability of the CREB-binding protein\/beta-Catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study","volume":"9","author":"Kimura","year":"2022","journal-title":"BMJ Open Gastroenterol"},{"key":"2025073013463161000_11.1.e001341.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01374-X"},{"key":"2025073013463161000_11.1.e001341.14","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000194238.15831.c7"},{"key":"2025073013463161000_11.1.e001341.15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ebiom.2017.08.016","article-title":"Safety, PRI-724, a CBP\/beta-Catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: A single-center, open-label, dose escalation phase 1 trial","volume":"23","author":"Kimura","year":"2017","journal-title":"EBioMedicine"},{"key":"2025073013463161000_11.1.e001341.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.02.008"},{"key":"2025073013463161000_11.1.e001341.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.050"},{"key":"2025073013463161000_11.1.e001341.18","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01094-19","article-title":"Pharmacological modulation of the WNT\/beta-Catenin pathway inhibits proliferation and promotes differentiation of long-lived memory Cd4(+) T cells in antiretroviral therapy-suppressed Simian immunodeficiency virus-infected macaques","volume":"94","author":"Mavigner","year":"2019","journal-title":"J Virol"},{"key":"2025073013463161000_11.1.e001341.19","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-11-91","article-title":"Non-invasive markers for hepatic fibrosis","volume":"11","author":"Baranova","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"2025073013463161000_11.1.e001341.20","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jgh.14008","article-title":"Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: results from a 5-year cohort study","volume":"33","author":"Facciorusso","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025073013463161000_11.1.e001341.21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbadis.2017.12.001","article-title":"Inhibition of Canonical WNT signaling pathway by beta-Catenin\/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of Stromal Cxcl12","volume":"1864","author":"Akcora","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2025073013463161000_11.1.e001341.22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00193.2016"},{"key":"2025073013463161000_11.1.e001341.23","doi-asserted-by":"crossref","first-page":"101809","DOI":"10.1016\/j.arr.2022.101809","article-title":"Cxcl12\/Cxcr4: an amazing challenge and opportunity in the fight against fibrosis","volume":"83","author":"Wu","year":"2023","journal-title":"Ageing Res Rev"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2023-001341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:46:38Z","timestamp":1753908398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2023-001341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,27]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjgast-2023-001341"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2023-001341","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}